Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, United States
Auto-generated profile, based on publicly available information
Dandan Wang
Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, and Howard Hughes Medical Institute, Boston, MA, United States
Human carboxylesterase 1 (hCE1), plays pivotal roles in endobiotics homeostasis and xenobiotic metabolism. The plasma level of hCE1 could serve as a useful serologic biomarker for several hepatic diseases, such as hepatocellular carcinoma. However, no probe reaction has been fruitfully used to determine the activity of trace hCE1 in human plasma. This study aims to design and develop a highly selective marker reaction for measuring the enzymatic activities of hCE1 in complex biological samples including human plasma. N-(4-Methyl butyrate)-4-hydroxy-1,8-naphthalimide (NMHN), which contains a small alcohol group and a large acyl moiety, was intentionally designed based on the substrate preference of hCE1. NMHN could be easily hydrolyzed by hCE1 with very high catalytic efficacy under physiological conditions, while both reaction-phenotyping assays and chemical inhibition assays demonstrated that this reaction exhibited super selectivity towards hCE1 over other human hydrolases. Furthermore, the marker reaction possessed ideal kinetic behaviour (classic Michaelis–Menten) with high intrinsic clearance (5.8 mL min−1 mg−1). Based on this probe, a rapid hCE1 quantification method was developed and fully validated, which was successfully applied to determine the real activities of hCE1 in various biological samples including human plasma. Our findings afforded a promising tool for measuring the real activity of hCE1 and laid a solid foundation for further investigations on the biological functions of hCE1 in complex biological samples.
Environmental adaptation often involves a shift in energy utilization toward mitochondrial fatty acid oxidation, which requires carnitine. Besides dietary sources of animal origin, carnitine biosynthesis from trimethyllysine (TML) is essential, particularly for those who consume plant-based diets; however, its molecular regulation and physiological role remain elusive. Here, we identify SLC25A45 as a mitochondrial TML carrier that controls carnitine biosynthesis and fuel switching. SLC25A45 deficiency decreased the carnitine pool and impaired mitochondrial fatty acid oxidation, shifting reliance to carbohydrate metabolism. Slc25a45 -deficient mice were cold-intolerant and resistant to lipid mobilization by glucagon-like peptide-1 receptor agonist (GLP-1RA), rendering them resistant to adipose tissue loss. Our study suggests that mitochondria serve as a regulatory checkpoint in fuel switching, with implications for metabolic adaptation and the efficacy of GLP-1RA–based anti-obesity therapy.
SUMMARY: Mitochondria provide a variety of metabolites, in addition to ATP, to meet cell-specific needs. One such metabolite is phosphoenolpyruvate (PEP), which contains a higher-energy phosphate bond than ATP and has diverse biological functions. However, how mitochondria-generated PEP is delivered to the cytosol and fulfills cell-specific requirements remains elusive. Here, we show that SLC25A35 regulates mitochondrial PEP efflux and glyceroneogenesis in lipogenic cells that utilize the pyruvate-to-PEP bypass. Reconstitution and structural studies demonstrated PEP transport by SLC25A35 in a pH gradient-dependent manner. Loss of SLC25A35 in adipocytes impaired the conversion of mitochondrial PEP into glycerol-3-phosphate, thereby reducing glycerolipid synthesis. Significantly, hepatic inhibition of SLC25A35 in obese mice alleviated steatosis and improved systemic glucose homeostasis. Together, these results suggest that mitochondria facilitate glycerolipid synthesis by providing PEP via SLC25A35, offering lipogenic mitochondria as a target to limit glycerolipid synthesis, a pivotal step in the pathogenesis of hepatic steatosis and Type 2 diabetes.
Metabolic adaptation to nutrient deprivation requires coordinated control of mitochondrial anaplerosis and cataplerosis; however, how metabolite flux across the mitochondrial membrane is regulated during fasting remains less defined. Here, we report SLC25A34 as a fasting-inducible mitochondrial carrier that is highly expressed in oxidative skeletal muscle. Using bacterial reconstitution, proteo-liposomes, and tracer studies, we showed that SLC25A34 mediates the import of phosphoenolpyruvate (PEP) into the mitochondrial matrix. Loss of SLC25A34 impaired glutamine-supported anaplerosis under nutrient-deprived conditions, while glucose and pyruvate utilization remained largely intact. Muscle-specific deletion of Slc25a34 resulted in reduced fasting-induced amino acid catabolism and the accumulation of amino acids, leading to activation of mTORC1 signaling even under fasted conditions. Consequently, SLC25A34-deficient soleus muscle exhibited hypertrophy and myopathic features, accompanied by mTORC1-dependent increase in protein synthesis. Together, these results highlight a unique biological role for the inducible mitochondrial carrier SLC25A34, which couples PEP import to amino acid catabolism and proteostasis to preserve skeletal muscle integrity in response to metabolic stress.